Advertisement

Factors affecting inadequate response to HBV vaccine in hemodialysis patients: northeast anatolia survey with six hemodialysis centers

  • Halil İbrahim ErdoğduEmail author
  • Eray Atalay
  • Gül Gürsoy
  • Başol Canbakan
  • Serkan Aktürk
  • Canan Yazıcı
  • Orhan Yücel
  • Sinan Mersin
  • Sengül Üçer
  • Özgür Merhametsiz
  • Can Öner
  • Merve Erat
Original article

Abstract

Background

In hemodialysis patients Hepatitis B virus (HBV) infection is one of the problems. Because of HBV vaccine response is lower than in the general population, in this study it is aimed to determine the factors that may cause inadequate HBV vaccine response in hemodialysis patients.

Methods

In study, HBsAg, anti-HBs, anti-HBc IgG data belonging to 278 patients were obtained from file and computer records. It was seen that seronegative cases had been given recombinant HBV vaccine. Anti-HBs titers were monitored 1 month after vaccination was completed. According to this, the patients are divided into two groups. Those with anti-HBs < 10 IU/mL were identified as non-responders and with anti-HBs ≥ 10 IU/mL as responders. Factors such as age, serum albumin and urea reduction rate which may affect inadequate response to HBV vaccine were evaluated. As statistical examination, Chi-square test was used for the analysis of the data determined by counting, and logistic regression was used for statistically significant independent variables in chi-square test. p value of < 0.05 was considered statistically significant (Confidence interval: 95%).

Results

Out of 278 patients, according to exclusion criteria 81 patients were excluded. 13.2%(26/197) of HBV vaccinated patients had insufficient response. The inadequate response rate to HBV vaccination was found to be higher in patients with age ≥ 65 (p = 0.039), serum albumin < 3.5 g/dL (p = 0.024) and urea reduction rate ≤ 65 (p = 0.028). No statistically significant relationship was found between inadequate response to HBV vaccine and anti-HCV positivity, presence of diabetes mellitus, anemia status, vitamin D therapy and vascular access pathway variability.

Conclusion

We conclude that relatively high patient age, low albumin level and insufficient urea reduction rate may cause inadequate HBV vaccine response. Taking these factors into consideration may provide a useful insight for an adequate response to vaccination.

Keywords

Hepatitis B vaccines Hemodialysis Humoral immune response Hemodialysis adequacy 

Notes

Acknowledgements

We would also thank to Associate Professor Dr. Binali Catak, from the Department of Public Health for his contribution.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The study protocol was approved by the Ethics Committee for Clinical Research, Faculty of Medicine, Kafkas University, Kars, Turkey. Our study was conducted according to the declaration of Helsinki. Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    World Health Organization. Hepatitis B. Fact sheet Reviewed July 2017. http://www.who.int/mediacentre/factsheets/fs204/en/. Accessed 10 Nov 2017.
  2. 2.
    Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–55.CrossRefGoogle Scholar
  3. 3.
    Blachier M, Leleu H, Peck-Radosavljevic M, et al. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013;58:593–608.CrossRefGoogle Scholar
  4. 4.
    Toy M, Onder FO, Wörmann T, et al. Age-and region-specific hepatitis B prevalence in Turkey estimated using generalized linear mixed models: a systematic review. BMC Infec Dis. 2011;11:337–46.CrossRefGoogle Scholar
  5. 5.
    Alter MJ, Arduino MJ, Lyerla HC, et al. Recommendations for preventing transmission of infections among chronic hemodialysis patients. CDC Public Health Recomm Rep. 2001;50:1–43.Google Scholar
  6. 6.
    Dinits-Pensy M, Forrest GN, Cross AS, et al. The use of vaccines in adult patients with renal disease. Am J Kidney Dis. 2005;46:997–1011.CrossRefGoogle Scholar
  7. 7.
    Hemodialysis. Adequacy 2006 Work Group. Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis. 2006;48:2–90.CrossRefGoogle Scholar
  8. 8.
    Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol. 1993;4:1205–13.PubMedGoogle Scholar
  9. 9.
    National Kidney Foundation. KDOQI clinical practice guideline and clinical practice recommendations: hemodialysis adequacy, peritoneal dialysis adequacy, and vascular access: update 2006. Am J Kidney Dis. 2006;48:1–322.CrossRefGoogle Scholar
  10. 10.
    Port FK, Pisoni RL, Bragg-Gresham JL, et al. DOPPS estimates of patient life years attributable to modifiable hemodialysis practices in the United States. Blood Purif. 2004;22:175–80.CrossRefGoogle Scholar
  11. 11.
    HAMAGUCHI N, KOBAYASHI M, HIRABAYASHI A, et al. T lymphocyte subpopulations in patients undergoing chronic hemodialysis. Jpn J Nephrol. 1984;26:1205–12.Google Scholar
  12. 12.
    Seyahi 12N, Altiparmak MR, Ates K, et al. Current status of renal replacement therapy in Turkey: a summary of Turkish society of nephrology 2014 annual registry report. Turk Neph Dial Transpl. 2015;24:10–6.CrossRefGoogle Scholar
  13. 13.
    Peces R, de la Torre M, Alcazar R, et al. Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients. Am J Kidney Dis. 1997;29:239–45.CrossRefGoogle Scholar
  14. 14.
    Fernandez E, Betriu MA, Gomez R. etal: Response to the hepatitis B virus vaccine in hemodialysis patients: Influence of malnutrition and its importance as a risk factor for morbidity and mortality. Nephrol Dial Transpl. 1996;11:1559–63.CrossRefGoogle Scholar
  15. 15.
    Fabrizi F, Martin P, Dixit V, et al. Meta-analysis: the effect of age on immunological response to hepatitis B vaccine in endstage renal disease. Aliment Pharmacol Ther. 2004;20:1053–62.CrossRefGoogle Scholar
  16. 16.
    Asan A, Demirhan H, Sorgun H, et al. Factors affecting responsiveness to hepatitis B immunization in dialysis patients. Int Urol Nephrol. 2017;49:1845–50.CrossRefGoogle Scholar
  17. 17.
    Novarro JF, Teruel JL, Mateos ML, et al. Antibody level after hepatitis B vaccination in hemodialysis patients; influence of hepatitis C virus infection. Am J Nephrol. 1996;16:95–7.CrossRefGoogle Scholar
  18. 18.
    Pera A, Campos C, Lopez N, et al. Immunosenescence: implications for response to infection and vaccination in older people. Maturitas. 2015;82:50–5.CrossRefGoogle Scholar
  19. 19.
    Pawelec G. T-cell immunity in the aging human. Haematologica. 2014;99:795–7.CrossRefGoogle Scholar
  20. 20.
    Chaves SS, Daniels D, Cooper BW, et al. Immunogenicity of hepatitis B vaccine among hemodialysis patients: effect of revaccination of non-responders and duration of protection. Vaccine. 2011;29:9618–23.CrossRefGoogle Scholar
  21. 21.
    Salva I, Sharaf ED, Bazzal I. Antibody level after hepatitis-B vaccination in hemodialysis patients: impact of dialysis adequacy, chronic inflammation, local endemicity and nutritional status. J Natl Med Assoc. 2006;98:1953–7.Google Scholar
  22. 22.
    Girndt M, Sester M, Sester U, et al. Defective expression of B7-2 (CD86) on monocytes of dialysis patients correlates to the uremia-associated immune defect. Kidney Int. 2001;59:1382–9.CrossRefGoogle Scholar
  23. 23.
    Gasim GI, Bella A, Adam I. Immune response to hepatitis B vaccine among patients on hemodialysis. World J Hepatol. 2015;7:270–5.CrossRefGoogle Scholar
  24. 24.
    Sorkhi H, Roushan MRH, Al Hashemi GH, et al. Response to hepatitis B virus vaccination in haemodialysis patients with and without hepatitis C infection. La Revue de Santé de la Méditerranée orientale. 2008;14:798–803.Google Scholar
  25. 25.
    Fabrizi F, Dixit V, Martin P. Meta-analysis: the impact of diabetes mellitus on the immunological response to hepatitis B virus vaccine in dialysis patients. Aliment Pharm Ther. 2011;33:815–21.CrossRefGoogle Scholar
  26. 26.
    Fabrizi F, Dixit V, Martin P, et al. Erythropoietin use and immunogenicity of hepatitis B virus vaccine in chronic kidney disease patients: a meta-analysis. Kidney Blood Press R. 2012;35:504–10.CrossRefGoogle Scholar
  27. 27.
    KDOQI, National Kidney Foundation: II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47: S16–85.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2018

Authors and Affiliations

  • Halil İbrahim Erdoğdu
    • 1
    Email author
  • Eray Atalay
    • 1
  • Gül Gürsoy
    • 2
  • Başol Canbakan
    • 3
  • Serkan Aktürk
    • 4
  • Canan Yazıcı
    • 5
  • Orhan Yücel
    • 4
  • Sinan Mersin
    • 6
  • Sengül Üçer
    • 7
  • Özgür Merhametsiz
    • 8
  • Can Öner
    • 9
  • Merve Erat
    • 1
  1. 1.Department of Internal MedicineHealth Research Center, Kafkas UniversityKarsTurkey
  2. 2.Department of Internal Medicine and EndocrinologyKafkas UniversityKarsTurkey
  3. 3.Department of Internal Medicine and NeprologyKafkas UniversityKarsTurkey
  4. 4.Department of Hemodialysis and NephrologyKars Harakani State HospitalKarsTurkey
  5. 5.Departement of Internal MedicineArdahan State HospitalArdahanTurkey
  6. 6.Department of Internal MedicineKartal Lütfi Kırdar Education and Research HospitalIstanbulTurkey
  7. 7.Department of Clinical Microbiology and Infectious diseasesKafkas UniversityKarsTurkey
  8. 8.Department of Hemodialysis and NephrologyIğdır State HospitalIğdırTurkey
  9. 9.Department of Family MedicineKartal Lütfi Kırdar Education and Research HospitalIstanbulTurkey

Personalised recommendations